Table 3.

Clinical outcomes in breast cancer patients by best response

Patient no.AgeER/PRHer2/neuNo. prior chemoregimensTime since last chemo (mo)Baseline CEA (ng/mL)Baseline CA 27.29 (U/mL)Best responsePFS (mo)OS (mo)
862ER+, PRNegative51153.6PD12.8
1762ER+, PRNegative6495.2276PD14.9
1257ER, PRNegative3471.4254PD225.3
1365ER+, PR+Negative3148.6182PD214.2
2145ER, PRNegative321.778.9PD24.9
2548ER, PR+Negative621.352.2PD22.7
2251ER+, PR+Negative2194.2151PD331.3
2375ER, PRNegative211.836.5SD411.2
2665ER, PRPositive0N/Ab8.416.2SD524.7
149ER+, PRNegative322.7SD, 20% ↓642.9
1666ER, PRNegative350.723.1SD, 17% ↓1013.0c
24a32ER+, PR+Positive1120.7<12.0CR37+37.0+

Abbreviations: OS, overall survival; PFS, progression-free survival; PD, progressive disease; SD, stable disease; CR, complete response.

  • aPatient still on study.

  • bPatient refused chemotherapy.

  • cNo further follow-up from this patient after this point.